Shots:

• Recursion to receive $150M up front & is eligible to receive additional research milestones, $300M upon the achievement of development, commercialization milestones along with royalties on net sales while Roche and Genentech will initiate 40 programs
• The collaboration will use the Recursion’s Operating System (OS) to identify novel targets and advance the therapies in neuroscience & oncology indication by using machine learning and high content screening methods generated from the collaboration's maps of human cellular biology
• The collaboration highlights the potential of technology to transform drug discovery and unlock previous unknown insights into complex disease

 Ref: Recursion | Image: Roche